Australian Doctor Australian Doctor 30th June 2017 | страница 20

Meningococcal B
can change life
in a moment
10:00 PM
1,2
Multicomponent Meningococcal group B vaccine
(recombinant, adsorbed)
NOW BACK IN STOCK :
PRESCRIBE WITH CONFIDENCE
3
10:00 AM
PBS Information: This product is not listed on the National Immunisation Program (NIP) or the PBS.
PLEASE REVIEW BEXSERO PRODUCT INFORMATION BEFORE PRESCRIBING.
FULL PRODUCT INFORMATION IS AVAILABLE AT AU.GSK.COM
Bexsero ® Minimum Product Information: Multicomponent Meningococcal group B vaccine (recombinant, adsorbed) Indications: Active immunisation
against invasive disease caused by N. meningitidis group B from 2 months of age. Contraindications: Hypersensitivity to any vaccine component. Precautions:
Bexsero should never be administered intravenously, subcutaneously or intradermally. Postpone vaccination during acute severe febrile illness. Anticipate
psychogenic response (syncope, hyperventilation). Manage fever (prophylactic antipyretics). Individuals with impaired immune responsiveness. No data for
use in subjects aged ≥50 years or patients with chronic medical conditions. Apnoea in very premature infants. Kanamycin-sensitive individuals. Pregnancy
(category B1). Lactation. May contain latex. Interactions: Can be given with DTPa, Hib, IPV, HepB, PCV7, MMR and V. Immunogenicity of Bexsero or routine
vaccines is unaffected by prophylactic paracetamol. Bexsero should be administered at separate injection sites. Adverse reactions: Infants & Toddlers: eating
disorders, sleepiness, unusual crying, diarrhoea, vomiting, rash, fever (≥39.5°C), injection site reactions, irritability. Adolescents & Adults: headache, nausea,
injection site reactions, malaise, myalagia, arthralgia. This is not a full list. Dosage and Administration: Administered by deep intramuscular injection.
0.5ml dose in a pre-filled syringe. Infants (2–5 months): 3 doses (≥1 month interval), booster dose at 12–23 months. Unvaccinated infants (6–11 months):
2 doses (≥2 month interval), booster dose at 12–23 months (≥2 month interval between primary series and booster). Unvaccinated toddlers and children
(12 months–10 years): 2 doses (≥2 month interval), need for booster not established. 11–50 years: 2 doses (≥1 month interval), need for booster not
established. Storage: Between +2°C and 8°C. DO NOT FREEZE. Protect from light. For further information, please refer to the full PI. [Bexsero min PI v02].
References: 1. van Deuren M et al. Clin Microbiol Rev 2000; 13(1): 144–66. 2. Thompson MJ et al. Lancet 2006; 367(9508): 397–403.
3. http://au.gsk.com/en-au/media/press-releases.
Not a real patient. Image is re-creation of a real case of meningococcal disease.
For information on GSK products or to report an adverse event involving a GSK product, please contact GSK Medical Information on 1800 033 109. GlaxoSmithKline
Australia Pty Ltd. ABN 47 100 162 481. Melbourne, VIC. Trade marks are owned by or licensed to the GSK group of companies © 2017 GSK group of companies or
its licensor AUS/BEX/0068/17b. Date of Approval May 2017. BEX0041/AD.